TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation After Coronary Bypass Grafting: Home Based Rehabilitation Versus Rehabilitation in Institution and Rehabilitation in Institution Versus Out-patient Rehabilitation at the Hospital
Brief Summary: The purpose of this study is to compare different types of rehabilitation after coronary bypass surgery. The investigators wish to compare rehabilitation in an institution for four weeks with a home based rehabilitation. They also wish to compare rehabilitation in an institution for four weeks with a rehabilitation program were the patients live at home but visit the hospital twice a week for twelve week. The investigators will measure the patients' physical capacity by measuring their maximal oxygen consumption. The investigators will also analyze their blood and their endothelian function (how well their arteries dilate).


Options:
A: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: vCRP; Type: EXPERIMENTAL; Interventions: Behavioral: vCRP | Intervention Type: BEHAVIORAL; Name: vCRP; Assigned to Arm(s): vCRP
B: Arm Label: OPTICARE-A; Type: EXPERIMENTAL; Interventions: Other: rehabilitation+telephonic coaching | Arm Label: OPTICARE-B; Type: ACTIVE_COMPARATOR; Interventions: Other: OPTICARE-B | Arm Label: OPTICARE-C; Type: EXPERIMENTAL; Interventions: Other: OPTICARE-C | Intervention Type: OTHER; Name: rehabilitation+telephonic coaching; Assigned to Arm(s): OPTICARE-A | Intervention Type: OTHER; Name: OPTICARE-B; Assigned to Arm(s): OPTICARE-B | Intervention Type: OTHER; Name: OPTICARE-C; Assigned to Arm(s): OPTICARE-C
C: Arm Label: Early Appointment; Type: EXPERIMENTAL; Interventions: Behavioral: Early appointment (within 10 days) | Arm Label: Standard Referral; Type: PLACEBO_COMPARATOR; Interventions: Other: Routine referral (at 5 weeks) | Intervention Type: BEHAVIORAL; Name: Early appointment (within 10 days); Assigned to Arm(s): Early Appointment | Intervention Type: OTHER; Name: Routine referral (at 5 weeks); Assigned to Arm(s): Standard Referral
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation After Coronary Bypass Grafting: Home Based Rehabilitation Versus Rehabilitation in Institution and Rehabilitation in Institution Versus Out-patient Rehabilitation at the Hospital
Brief Summary: The purpose of this study is to compare different types of rehabilitation after coronary bypass surgery. The investigators wish to compare rehabilitation in an institution for four weeks with a home based rehabilitation. They also wish to compare rehabilitation in an institution for four weeks with a rehabilitation program were the patients live at home but visit the hospital twice a week for twelve week. The investigators will measure the patients' physical capacity by measuring their maximal oxygen consumption. The investigators will also analyze their blood and their endothelian function (how well their arteries dilate).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prehab Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Prehab Intervention | Intervention Type: BEHAVIORAL; Name: Prehab Intervention; Assigned to Arm(s): Prehab Intervention
D: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation
Brief Summary: This randomized double-blind, placebo-controlled will determine the relative efficacy of standard versus extended transdermal nicotine (TN) therapy for smoking cessation. After completing the eligibility screening, 600 treatment-seeking smokers will be randomized to receive either standard treatment (ST) with TN (21mg x 8 weeks, placebo x 16 weeks) or extended treatment (ET) with TN (21mg x 24 weeks). All participants will receive behavioral counseling. The primary outcome will be biochemically verified abstinence from smoking at the end of treatment (week 24). Secondary outcomes include abstinence at week 28 (4 weeks after treatment is discontinued), and time to failure. We hypothesize that ET will produce significantly higher quit rates than ST; however, the benefit of ET will last only so long as treatment is continued. Support for this hypothesis would indicate that maintenance therapy with TN should be considered.


Options:
A: Arm Label: Male Naltrexone; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone (drug) | Arm Label: Female Naltrexone; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone (drug) | Arm Label: Male Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Naltrexone) | Arm Label: Female Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Naltrexone) | Intervention Type: DRUG; Name: Naltrexone (drug); Assigned to Arm(s): Female Naltrexone, Male Naltrexone | Intervention Type: DRUG; Name: Placebo (for Naltrexone); Assigned to Arm(s): Female Placebo, Male Placebo
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
D: Arm Label: APD356 10 mg b.i.d.; Type: EXPERIMENTAL; Interventions: Drug: APD356-lorcaserin hydrochloride | Arm Label: APD356 10 mg q.d.; Type: EXPERIMENTAL; Interventions: Drug: APD356-lorcaserin hydrochloride | Arm Label: Placebo 10 mg b.i.d; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: APD356-lorcaserin hydrochloride; Assigned to Arm(s): APD356 10 mg b.i.d., APD356 10 mg q.d. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 10 mg b.i.d

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation
Brief Summary: This randomized double-blind, placebo-controlled will determine the relative efficacy of standard versus extended transdermal nicotine (TN) therapy for smoking cessation. After completing the eligibility screening, 600 treatment-seeking smokers will be randomized to receive either standard treatment (ST) with TN (21mg x 8 weeks, placebo x 16 weeks) or extended treatment (ET) with TN (21mg x 24 weeks). All participants will receive behavioral counseling. The primary outcome will be biochemically verified abstinence from smoking at the end of treatment (week 24). Secondary outcomes include abstinence at week 28 (4 weeks after treatment is discontinued), and time to failure. We hypothesize that ET will produce significantly higher quit rates than ST; however, the benefit of ET will last only so long as treatment is continued. Support for this hypothesis would indicate that maintenance therapy with TN should be considered.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Practice Quit Attempt plus nicotine lozenge | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Practice Quit Attempt only | Intervention Type: OTHER; Name: Practice Quit Attempt plus nicotine lozenge; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Practice Quit Attempt only; Assigned to Arm(s): 2
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine versus placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: nicotine versus placebo | Intervention Type: DRUG; Name: nicotine versus placebo; Assigned to Arm(s): A, B
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nasal Spray Nicotine Substitute (Experimental) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal Spray Nicotine Substitute (ad libitum) | Intervention Type: DRUG; Name: Nasal Spray Nicotine Substitute (Experimental); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nasal Spray Nicotine Substitute (ad libitum); Assigned to Arm(s): 2
D: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation
Brief Summary: This randomized double-blind, placebo-controlled will determine the relative efficacy of standard versus extended transdermal nicotine (TN) therapy for smoking cessation. After completing the eligibility screening, 600 treatment-seeking smokers will be randomized to receive either standard treatment (ST) with TN (21mg x 8 weeks, placebo x 16 weeks) or extended treatment (ET) with TN (21mg x 24 weeks). All participants will receive behavioral counseling. The primary outcome will be biochemically verified abstinence from smoking at the end of treatment (week 24). Secondary outcomes include abstinence at week 28 (4 weeks after treatment is discontinued), and time to failure. We hypothesize that ET will produce significantly higher quit rates than ST; however, the benefit of ET will last only so long as treatment is continued. Support for this hypothesis would indicate that maintenance therapy with TN should be considered.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
B: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
C: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glycemic Load and Infant Birth Weight in Pregnant Overweight/Obese Women
Brief Summary: This study will compare the effects of a low glycemic load versus standard diet for pregnancy on outcomes related to risk for obesity, diabetes, and heart disease in both mother and infant.


Options:
A: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
B: Arm Label: Intensive Counseling Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary and lifestyle counseling | Arm Label: Routine care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary and lifestyle counseling; Assigned to Arm(s): Intensive Counseling Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
D: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glycemic Load and Infant Birth Weight in Pregnant Overweight/Obese Women
Brief Summary: This study will compare the effects of a low glycemic load versus standard diet for pregnancy on outcomes related to risk for obesity, diabetes, and heart disease in both mother and infant.


Options:
A: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and dietary education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise and dietary education; Assigned to Arm(s): Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
D: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glycemic Load and Infant Birth Weight in Pregnant Overweight/Obese Women
Brief Summary: This study will compare the effects of a low glycemic load versus standard diet for pregnancy on outcomes related to risk for obesity, diabetes, and heart disease in both mother and infant.


Options:
A: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
B: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glycemic Load and Infant Birth Weight in Pregnant Overweight/Obese Women
Brief Summary: This study will compare the effects of a low glycemic load versus standard diet for pregnancy on outcomes related to risk for obesity, diabetes, and heart disease in both mother and infant.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
B: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Intervention
D: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: Lifestyle intervention, Behavioral: Physical activity, dietetic counselling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Control | Intervention Type: OTHER; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Physical activity, dietetic counselling; Assigned to Arm(s): Lifestyle intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Active-Control, Parallel-Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee
Brief Summary: The purpose of this study is to evaluate the safety of CG5503 base Immediate Release(IR) 50 mg or 100 mg taken every 4 to 6 hours as needed over the long-term exposure of 90 days in patients who have chronic pain.


Options:
A: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
B: Intervention Type: DRUG; Name: glucosamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chondroitin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glucosamine and chondroitin sulfate combined; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): N/A
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone IR | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol ER (CG5503) | Arm Label: 006; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone CR | Arm Label: 007; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone CR; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: oxycodone IR; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Tapentadol ER (CG5503); Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 007
D: Intervention Type: DRUG; Name: CG 5503;tapentadol; Assigned to Arm(s): N/A

Answer: D